Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics

RARE POWR Grades

• Value is the dimension where RARE ranks best; there it ranks ahead of 69.37% of US stocks.
• RARE's strongest trending metric is Growth; it's been moving down over the last 179 days.
• RARE ranks lowest in Momentum; there it ranks in the 21st percentile.

RARE Stock Summary

• Of note is the ratio of ULTRAGENYX PHARMACEUTICAL INC's sales and general administrative expense to its total operating expenses; only 14.79% of US stocks have a lower such ratio.
• For RARE, its debt to operating expenses ratio is greater than that reported by just 10.3% of US equities we're observing.
• With a price/sales ratio of 9.85, ULTRAGENYX PHARMACEUTICAL INC has a higher such ratio than 88.01% of stocks in our set.
• If you're looking for stocks that are quantitatively similar to ULTRAGENYX PHARMACEUTICAL INC, a group of peers worth examining would be MRKR, EDIT, FDMT, CYCN, and LVTX.
• RARE's SEC filings can be seen here. And to visit ULTRAGENYX PHARMACEUTICAL INC's official web site, go to www.ultragenyx.com.

RARE Valuation Summary

• RARE's price/earnings ratio is -6.7; this is 131.16% lower than that of the median Healthcare stock.
• Over the past 104 months, RARE's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for RARE.

RARE Growth Metrics

The 4 year price growth rate now stands at 3.19%.
• Its 2 year price growth rate is now at -8.84%.
• Its 2 year cash and equivalents growth rate is now at -48.36%.

RARE's revenue has moved up $249,932,000 over the prior 33 months.

The table below shows RARE's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-06-30	334.314	-308.771	-505.938
2022-03-31	331.946	-296.87	-470.204
2021-12-31	351.406	-338.695	-454.025
2021-09-30	359.559	-346.803	-355.578
2021-06-30	359.382	-349.121	-351.425
2021-03-31	334.116	-196.414	-203.682

RARE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• RARE has a Quality Grade of D, ranking ahead of 11.33% of graded US stocks.
• RARE's asset turnover comes in at 0.234 -- ranking 185th of 681 Pharmaceutical Products stocks.
• ADMS, AVDL, and QGEN are the stocks whose asset turnover ratios are most correlated with RARE.

The table below shows RARE's key quality metrics over time.